Opinion
Video
Breaking Down the PAH Cost Burden
Author(s):
Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.
Video Player is loading.
Video content above is prompted by the following questions:
- What are the direct medical costs and indirect socioeconomic costs associated with managing pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and impacts on patient productivity and quality of life?
- How does the overall burden of PAH, in terms of clinical outcomes and resource utilization, vary across different patient populations and health care settings? Are there any disparities that clinicians and payers should be more aware of?
Related Videos
ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach
Tailoring HS Treatment: The Path to Better Patient Outcomes
Advancing HS Outcomes: Resource Prioritization and Success Measurement
Future Directions and Overcoming Challenges in BTK Inhibitor Therapy
Navigating HS Management: The Patient Journey
Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence
Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
Implementation of Shared Decision-Making in BTK Inhibitor Treatment
The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
Related Content
